Search
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.
Ciforadenant
go.drugbank.com/drugs/DB16125InvestigationalCiforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.
Primidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]
Risedronic acid
go.drugbank.com/drugs/DB00884ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedBy inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Phensuximide
go.drugbank.com/drugs/DB00832ApprovedThe frequency of attacks is reduced by depression of nerve transmission in the motor cortex.
Ginkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical_Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.